Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic Trial
Peter Bossuyt, Lieven Pouillon, Sophie Claeys, et al.
Journal of Crohn s and Colitis (2021) Vol. 16, Iss. 2, pp. 199-206
Closed Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives
Peter M. Irving, K Gecse
Gastroenterology (2022) Vol. 162, Iss. 5, pp. 1512-1524
Open Access | Times Cited: 73
Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
Nghia Nguyen, Virginia Solitano, Sudheer K. Vuyyuru, et al.
Gastroenterology (2022) Vol. 163, Iss. 4, pp. 937-949.e2
Open Access | Times Cited: 45
Meta‐analysis: The efficacy of therapeutic drug monitoring of anti‐TNF‐therapy in inflammatory bowel disease
Sonika Sethi, Shiluka Dias, Aditi Kumar, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 57, Iss. 12, pp. 1362-1374
Open Access | Times Cited: 43
Inflammation-fibrosis interplay in inflammatory bowel disease: mechanisms, progression, and therapeutic strategies
Yanan Li, Feng Xu, Yulai Fang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)
Konstantinos Papamichael, Vipul Jairath, Guangyong Zou, et al.
BMJ Open (2022) Vol. 12, Iss. 4, pp. e057656-e057656
Open Access | Times Cited: 25
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic
Simeng Lin, Louis Ho Shing Lau, Neil Chanchlani, et al.
Gut (2022) Vol. 71, Iss. 7, pp. 1426-1439
Open Access | Times Cited: 25
Precision medicine and drug optimization in adult inflammatory bowel disease patients
Sophie Vieujean, Édouard Louis
Therapeutic Advances in Gastroenterology (2023) Vol. 16
Open Access | Times Cited: 12
Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)
Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, et al.
Gastroenterología y Hepatología (2024) Vol. 47, Iss. 5, pp. 522-552
Open Access | Times Cited: 4
Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases
W Kantasiripitak, An Outtier, Sebastian G. Wicha, et al.
CPT Pharmacometrics & Systems Pharmacology (2022) Vol. 11, Iss. 8, pp. 1045-1059
Open Access | Times Cited: 20
Personalized Treatment for Crohn’s Disease: Current Approaches and Future Directions
Joseph Clinton, Raymond K. Cross
Clinical and Experimental Gastroenterology (2023) Vol. Volume 16, pp. 249-276
Open Access | Times Cited: 11
Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases
Konstantinos Papamichael, Gabriele Stocco, Ainhoa Ruiz del Agua
Therapeutic Drug Monitoring (2023) Vol. 45, Iss. 5, pp. 579-590
Open Access | Times Cited: 10
Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring
Farah Albader, Petra A. Golovics, Lóránt Gönczi, et al.
World Journal of Gastroenterology (2021) Vol. 27, Iss. 37, pp. 6231-6247
Open Access | Times Cited: 19
Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
Zvonimir Petrić, João Gonçalves, Paulo Paixão
Pharmaceutics (2022) Vol. 14, Iss. 9, pp. 1766-1766
Open Access | Times Cited: 12
Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease
Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Eirini Theodoraki, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 7, pp. 2452-2452
Open Access | Times Cited: 6
Recent developments in the assessment and management of inflammatory bowel disease in childhood: a narrative review
Zachary Green, R. Mark Beattie, James J. Ashton
Translational Pediatrics (2023) Vol. 12, Iss. 10, pp. 1853-1874
Open Access | Times Cited: 6
Therapeutic Drug Monitoring of Biologics in Crohn’s Disease
Laurie B. Grossberg, Adam S. Cheifetz, Konstantinos Papamichael
Gastroenterology Clinics of North America (2022) Vol. 51, Iss. 2, pp. 299-317
Closed Access | Times Cited: 10
Is tumor necrosis factor-α monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? Network meta-analysis
Fang-Yuan Zheng, Kaisi Yang, Wen-Cheng Min, et al.
World Journal of Gastrointestinal Surgery (2024) Vol. 16, Iss. 2, pp. 571-584
Open Access | Times Cited: 1
Efficacy of Early Optimization of Infliximab Guided by Therapeutic Drug Monitoring during Induction—A Prospective Trial
Karoline Soares Garcia, Matheus Freitas Cardoso de Azevedo, Alexandre de Sousa Carlos, et al.
Biomedicines (2023) Vol. 11, Iss. 6, pp. 1757-1757
Open Access | Times Cited: 4
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies
Konstantinos Papamichael, Adam S. Cheifetz
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 12, pp. 1423-1431
Closed Access | Times Cited: 7
Model-informed precision dosing in inflammatory bowel diseases
Arno R. Bourgonje, Marla C. Dubinsky, Ron J. Keizer, et al.
Trends in Pharmacological Sciences (2024)
Closed Access
Infliximab Precision Dosing in Inflammatory Bowel Disease (IBD) Patients: A Review of Current Literature
Alexandros Toskas, Magdalini Manti, Nikolaos Kamperidis, et al.
Cureus (2024)
Open Access
Pharmacist-Driven Therapeutic Infliximab Monitoring at the Point of Care Using Rapidly Assessed Drug Levels in Patients with Inflammatory Bowel Disease
Clarissa Rentsch, Mark G. Ward, Raphael P. Luber, et al.
Therapeutic Drug Monitoring (2022) Vol. 45, Iss. 3, pp. 383-391
Closed Access | Times Cited: 3
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis
Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, et al.
Gastroenterología y Hepatología (English Edition) (2024) Vol. 47, Iss. 5, pp. 522-552
Open Access
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study
Ashish Srinivasan, Daniel R. van Langenberg, Peter De Cruz, et al.
BioDrugs (2024) Vol. 38, Iss. 5, pp. 691-702
Open Access
Is therapeutic drug monitoring a dancing partner for TNF-α inhibitors in real-world practice? Answers from an updated systematic review and meta-analysis
Yang Hu, Zaiwei Song, Yuan Gao, et al.
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 10, pp. 935-948
Open Access
Page 1 - Next Page

Scroll to top